Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › AKTS

Aktis Oncology

AKTS Lead: Phase 1 4 Biotech Distilled articles ↓ 12 filings & releases ↓ Cash $82.5M (Jun 30, 2026) ↓ 4 verdicts ↓ 3 timing quotes ↓
Oncology PeptideRadioligand

Market cap $880M 55.6M shares (vendor count, Nov 7, 2026) × $15.82 close Nov 6, 2026 · share count from the market-data vendor, not the SEC cover page

Most recent annual filing: 2026-03-15

Catalyst timeline

5 trackedQuarter catalyst calendar →
  1. Aktis cGMP manufacturing facility update2H 2026Aktis cGMP manufacturing facility update, 2H 2026, routine
  2. cGMP facility manufacturing update2H 2026cGMP facility manufacturing update, 2H 2026, routine
  3. BActinium-2 trial start2H 2026BActinium-2 trial start, 2H 2026, routine
  4. AKY-1189 Ph1 interim1Q 2027AKY-1189 Ph1 interim, 1Q 2027, major
  5. Two early pipeline programs corporate1Q 2027Two early pipeline programs corporate, 1Q 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (10 active programs)

Technology platforms

miniprotein radioconjugate platform · Eli Lilly

Proprietary miniprotein radioconjugate platform using polypeptides of 40-70 amino acids to selectively deliver alpha- or beta-emitting radioisotopes to solid tumors with high tumor penetration, prolonged retention, and rapid clearance from normal tissues. Leverages yeast surface display, AI/generative AI, and medicinal chemistry for discovery. Collaboration with Eli Lilly to generate novel anticancer radiopharmaceuticals against additional targets beyond the company's unpartnered pipeline.

miniprotein radioconjugate platform · Eli Lilly and Company

Proprietary, isotope-agnostic miniprotein radioconjugate platform designed to selectively deliver radioisotopes to targeted tumors; enables high tumor penetration, internalization and retention, and rapid clearance from normal tissues; supports imaging and therapeutic isotopes; focused on solid tumors including prostate, lung, urothelial, and breast cancers

Capital (as filed)

Cash
$82.5M cash and cash equivalents · Jun 30, 2026 (10-Q)
Operating cash flow
−$20.6M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$517M cash, runway 2029 per the update of Aug 13, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (4)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (4 calls)

Every verdict Biotech Distilled has published on Aktis Oncology, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-04-30 Watch Aktis Oncology (AKTS) - Scientific Deep Dive for AKY1189 and Pipeline Products Miniprotein radiopharma platform is scientifically differentiated but lacks clinical validation; watch list with speculative accumulation only on broad market weakness ahead of mid-2026 and Q1 2027 catalysts.
  2. 2026-05-12 Speculative buy speculative UPDATE: Aktis Oncology (AKTS) - Fast Track, ASCO Date, and the Clock Starts on the Mid-2026 De-risker Fast Track designation and ASCO date for AKY-2519 dosimetry data sharpen the catalyst calendar; maintain speculative buy as the platform de-risker is imminent and cash runway is secure into 2029.
  3. 2026-05-21 Buy core UPDATE: Aktis Oncology (AKTS) - The Canary Sings AKY-2519 ASCO dosimetry data showed favorable kidney, bone marrow, and salivary gland doses with robust tumor uptake, confirming the renal engineering generalizes across a second miniprotein and materially de-risking the platform ahead of the Q1 2027 AKY-1189 binary.
  4. 2026-08-14 Buy core UPDATE: Aktis Oncology (AKTS) - Boring Quarter, Interesting Footnotes Q2 showed no new efficacy data but confirmed execution with three Phase 1b trials running, a widened lead trial indication, first Lilly milestone booked, and $517M cash runway into 2029; buy maintained though entry is 24% worse than post-ASCO.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (3 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (12)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 21, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

1 more filing (13G holder notices, S-8, proxy material, SEC correspondence …)